Tempus gains Buy rating on AI-driven diagnostics and expanding FDA approvals boosting clinical reach.

Tempus AI's healthcare data segment revenue jumps 40% YoY, targeting $500M+ in 2026.

Tempus AI, Inc. reported a 40% year-over-year increase in its healthcare data segment revenue for Q1 2026, reaching $87 million. This growth is driven by a surge in MRD testing volume, which rose 500% YoY due to a partnership with Personalis for a re...